Clinuvel Pharmaceuticals Ltd (CLVLY)
8.95
+0.01
(+0.11%)
USD |
OTCM |
Nov 13, 15:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 448.20M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -12.39% |
| Valuation | |
| PE Ratio | 19.52 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.896 |
| Price to Book Value | 3.303 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0340 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 72.96% |
Profile
| Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US. |
| URL | https://www.clinuvel.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Nov. 29, 2024 (est.) |
| Last Earnings Release | Aug. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 09, 2024 |
Ratings
Profile
| Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US. |
| URL | https://www.clinuvel.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Nov. 29, 2024 (est.) |
| Last Earnings Release | Aug. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 09, 2024 |